NCT05979051

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

A Multicenter, Single-arm/Randomized, Double-blind, Active-controlled, Parallel-group Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR-1703 for Patients With EGPA

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 166 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.

Conditions

• Eosinophilic Granulomatosis With Polyangiitis

Interventions

Type	Name	Description
DRUG	SHR-1703	SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
DRUG	Mepolizumab Injection	Mepolizumab Injection and Matching Placebo will be administered by Subcutaneous injection in Phase 3

Timeline

• Start date: 2023-11-16
• Primary completion: 2028-12-01
• Completion: 2028-12-01
• First posted: 2023-08-07
• Last updated: 2025-12-04

Locations

2 sites across 1 country: China